Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oral Cancer Drugs, MS Self-Injectables Covered In Medicare Pilot Program

Executive Summary

The Medicare conference agreement sets aside $200 mil. to pay for oral cancer therapies under a demonstration project

You may also be interested in...



Biogen Idec/Elan Tysabri Guaranteed Coverage Under Medicare Part B

Biogen Idec/Elan's once-monthly I.V. formulation of the multiple sclerosis therapy Tysabri guarantees that the product will be covered under Medicare Part B

Biogen Idec/Elan Tysabri Guaranteed Coverage Under Medicare Part B

Biogen Idec/Elan's once-monthly I.V. formulation of the multiple sclerosis therapy Tysabri guarantees that the product will be covered under Medicare Part B

Medicare Part B Oral Chemotherapy Demo Limited To Approved Indications

Reimbursement for oral chemotherapy products under a Medicare Part B demonstration project will be limited to FDA-approved indications, the Centers for Medicare & Medicaid Services' proposed criteria say

Related Content

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel